Brief: Neurocrine To Acquire Soleno Therapeutics, Expanding Its Endocrinology And Rare Disease Portfolio

Soleno Therapeutics

06/04/2026 12:17

April 6 (Reuters) - Neurocrine Biosciences Inc NBIX.O:

NEUROCRINE TO ACQUIRE SOLENO THERAPEUTICS, EXPANDING ITS ENDOCRINOLOGY AND RARE DISEASE PORTFOLIO

NEUROCRINE BIOSCIENCES INC - TO BUY SOLENO FOR $53 PER SHARE, EQUITY VALUE $2.9 BILLION

NEUROCRINE BIOSCIENCES INC - TENDER OFFER AT $53 PER SHARE, 34% PREMIUM TO APRIL 2, 2026 CLOSE

NEUROCRINE BIOSCIENCES INC - DEAL TO BE FUNDED WITH CASH ON HAND

NEUROCRINE BIOSCIENCES INC: BOARDS OF DIRECTORS OF BOTH COMPANIES HAVE APPROVED TRANSACTION

Source text: ID:nPn3bCcYRa

Further company coverage: NBIX.O

 ((Reuters.Briefs@thomsonreuters.com;))